Skip to main content
. 2015 Sep 2;3(6):1323–1328. doi: 10.3892/mco.2015.634

Figure 2.

Figure 2.

Survival curves of patient subgroups according to prognostic factors. (A) Patients with different primary sites (P<0.0001). (B) Patients with synchronous or metachronous disease (P=0.008). (C) Patients with or without disease beyond the ovary (P=0.0138). (D) Patients with or without ascites (P<0.0001). (E) Patients with or without chemotherapy (P=0.0796). (F) Patients with or without metastasectomy (P=0.0060).